Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
New research findings may soon help doctors personalize preterm birth prevention treatments by identifying which women at higher risk for preterm birth will be helped by progesterone injections.
Injections of one type of progesterone, a synthetic form of a hormone naturally produced during pregnancy, have been shown to reduce the risk of recurrent preterm births by about a third.
Nearly half a million babies are born too soon each year in the United States. Preterm birth (birth before 37 weeks of pregnancy) is the leading cause of newborn death, and babies who survive an early birth often face an increased risk of a lifetime of health challenges, such as breathing problems, cerebral palsy, intellectual disabilities and others. Even babies born just a few weeks early have higher rates of hospitalization and illness than full-term infants. It is a serious health problem that costs the United States more than $26 billion annually
Tracy Manuck, M.D., assistant professor of Maternal Fetal Medicine and co-director of the University of Utah Prematurity Prevention Clinic at University of Utah Health Care, has been working to understand why progesterone treatments prevent preterm birth for some women but not for others. She hopes to determine whether there is a way to personalize their treatment based on their genetic makeup. She presented her latest findings at the Society for Maternal-Fetal Medicine's 34th annual meeting, The Pregnancy Meeting™.
"This is the first step in using pharmacogenomics to prevent preterm birth," said Edward R.B. McCabe, MD, March of Dimes chief medical officer. "There is a group of women in whom progesterone will be effective and others for whom it will not be and who will need different treatments. Knowing which group a woman belongs to would fast track her to the proper treatment. The goal is to find personalized treatments that work for individuals to prevent preterm birth."
Dr. Manuck and her colleagues looked at 50 women followed in a prematurity prevention clinic at Intermountain Healthcare in Utah who received progesterone treatment and separated them by whether they responded to the treatment. The team then sequenced all of the areas of the women's genomes that code for proteins and looked for genetic differences between the two groups. The team identified several genes and general biologic pathways that were more likely to be expressed in women who did not respond to progesterone.
"Preterm birth is a complex health problem and it's unlikely that we will find a single genetic cause," said Dr. Manuck. "We know that not all women with a prior preterm birth can be helped by progesterone treatments, and we're trying to identify who those women are."
Dr. McCabe will present Dr. Manuck with the March of Dimes award for Best Abstract in Prematurity at the SMFM's Annual Meeting. 2014 marks the 11th year the March of Dimes award has been presented. Dr. Manuck is a two-time recipient of the honor. She was honored in 2009 for research that looked at progesterone receptors and progesterone response.
"Dr. Manuck has continued to focus her research on progesterone, but her methods have evolved. She has gone from the traditional hypothesis testing approach to a discovery science approach, scanning the landscape to find informative areas and inviting researchers from a variety of disciplines to collaborate with her," said Dr. McCabe. "She's doing important work because she's encouraging people to come out of their comfort zones and cross the boundaries between disciplines."
Abstract 9: Genetic Variation in Key Biologic Processes May Influence Response to 17-alpha hydroxyprogesterone Caproate (17P) for Recurrent Preterm Birth (PTB) Prevention
Authors: Tracy Manuck1, Scott Watkins2, M. Sean Esplin1, Michael Varner1, G. Marc Jackson1, Barry Moore2, Mark Yandell2, Lynn Jorde2
1Intermountain Healthcare and The University of Utah, Obstetrics and Gynecology, Salt Lake City, UT, 2The University of Utah, Human Genetics, Salt Lake City, UT
Objective: We hypothesized that genetic variation affects variable response to 17P for recurrent PTB prevention.
Study Design: Women with ≥1 spontaneous singleton PTB <34 wks who received 17P were recruited prospectively and classified as a 17P responder (RES) or non-responder (NRES) by the difference in delivery gest. age (GA) between 17P treated & untreated pregnancies. Illumina® HiSeq2000 whole exome sequencing technology genotyped each woman for ~180,000 protein-coding exons. Exomes were compared between RES and NRES women using the Variant Annotation, Analysis & Search Tool (VAAST), a probabilistic search tool for identifying disease-causing variants, & compared to a KEGG pathway candidate gene list. The top 2.5% of genes (n=470) with the highest VAAST scores were then selected for pathway analysis. Genes were classified by the online Protein ANalysis THrough Evolutionary Relationships (PANTHER) system into known gene ontology molecular functions & biologic processes. Gene distributions within these classifications were compared to an online referent population to search for areas of over- and under- representation. Bonferroni-corrected p-values are reported.
Results: 50 women (41 RES, 9 NRES, all European ancestry) were included. RES and NRES did not differ with regards to parity, CI hx, or PPROM hx. RES delivered, on avg, +9.2 wks longer with 17P vs. +1.3 wks for NRES (p<0.001). All samples met genotype quality filters, and the avg depth of exome coverage was 51 +/- 18. Our VAAST analysis allowed for recessive inheritance & locus heterogeneity. The NOS1 gene scored highest in VAAST among the KEGG-pathway identified candidate genes (Figure). PANTHER analysis revealed several over- represented biologic processes (Table).
Conclusion: Using a novel analytic approach, we have identified over-represented genes in key processes (incl. the biologically plausible NO signal pathway) among RES to 17P, the 1st step in applying pharmacogenomics to PTB prevention.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Pregnancy / Obstetrics category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Society for Maternal-Fetal Medicine. "First step in using pharmacogenomics for prevention of preterm birth." Medical News Today. MediLexicon, Intl., 5 Feb. 2014. Web.
23 Apr. 2014. <http://www.medicalnewstoday.com/releases/272134>
Society for Maternal-Fetal Medicine. (2014, February 5). "First step in using pharmacogenomics for prevention of preterm birth." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/272134.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.